All sources · 65,571 documents · Table of contents · FDA Reauthorization Act of 2017 · FDA Reauthorization Act of 2017
Statute Compilations
FDA Reauthorization Act of 2017
72 entries
Sec. 1
SHORT TITLE
Sec. 2
TABLE OF CONTENTS
Sec. 101
SHORT TITLE; FINDING
Sec. 102
AUTHORITY TO ASSESS AND USE DRUG FEES
Sec. 103
REAUTHORIZATION; REPORTING REQUIREMENTS
Sec. 105
EFFECTIVE DATE
Sec. 106
SAVINGS CLAUSE
Sec. 201
SHORT TITLE; FINDING
Sec. 202
DEFINITIONS
Sec. 203
AUTHORITY TO ASSESS AND USE DEVICE FEES
Sec. 204
REAUTHORIZATION; REPORTING REQUIREMENTS
Sec. 205
CONFORMITY ASSESSMENT PILOT PROGRAM
Sec. 206
REAUTHORIZATION OF REVIEW
Sec. 207
ELECTRONIC FORMAT FOR SUBMISSIONS
Sec. 208
SAVINGS CLAUSE
Sec. 209
EFFECTIVE DATE
Sec. 301
SHORT TITLE; FINDING
Sec. 302
DEFINITIONS
Sec. 303
AUTHORITY TO ASSESS AND USE HUMAN GENERIC DRUG FEES
Sec. 304
REAUTHORIZATION; REPORTING REQUIREMENTS
Sec. 306
EFFECTIVE DATE
Sec. 307
SAVINGS CLAUSE
Sec. 401
SHORT TITLE; FINDING
Sec. 402
DEFINITIONS
Sec. 403
AUTHORITY TO ASSESS AND USE BIOSIMILAR FEES
Sec. 404
REAUTHORIZATION; REPORTING REQUIREMENTS
Sec. 406
EFFECTIVE DATE
Sec. 407
SAVINGS CLAUSE
Sec. 501
BEST PHARMACEUTICALS FOR CHILDREN
Sec. 502
PEDIATRIC DEVICES
Sec. 503
EARLY MEETING ON PEDIATRIC STUDY PLAN
Sec. 504
DEVELOPMENT OF DRUGS AND BIOLOGICAL PRODUCTS FOR PEDIATRIC CANCERS
Sec. 505
ADDITIONAL PROVISIONS ON DEVELOPMENT OF DRUGS AND BIOLOGICAL PRODUCTS FOR PEDIATRIC USE
Sec. 601
REAUTHORIZATION OF PROVISION RELATING TO EXCLUSIVITY OF CERTAIN DRUGS CONTAINING SINGLE ENANTIOMERS
Sec. 602
REAUTHORIZATION OF THE CRITICAL PATH PUBLIC-PRIVATE PARTNERSHIPS
Sec. 603
REAUTHORIZATION OF ORPHAN GRANTS PROGRAM
Sec. 604
PROTECTING AND STRENGTHENING THE DRUG SUPPLY CHAIN
Sec. 605
PATIENT EXPERIENCE DATA
Sec. 606
COMMUNICATION PLANS
Sec. 607
ORPHAN DRUGS
Sec. 608
PEDIATRIC INFORMATION ADDED TO LABELING
Sec. 609
SENSE OF CONGRESS ON LOWERING THE COST OF PRESCRIPTION DRUGS
Sec. 610
EXPANDED ACCESS
Sec. 611
TROPICAL DISEASE PRODUCT APPLICATION
Sec. 701
RISK-BASED INSPECTIONS FOR DEVICES
Sec. 702
IMPROVEMENTS TO INSPECTIONS PROCESS FOR DEVICE ESTABLISHMENTS
Sec. 703
REAUTHORIZATION OF INSPECTION PROGRAM
Sec. 704
CERTIFICATES TO FOREIGN GOVERNMENTS FOR DEVICES
Sec. 705
FACILITATING INTERNATIONAL HARMONIZATION
Sec. 706
FOSTERING INNOVATION IN MEDICAL IMAGING
Sec. 707
RISK-BASED CLASSIFICATION OF ACCESSORIES
Sec. 708
DEVICE PILOT PROJECTS
Sec. 709
REGULATION OF OVER-THE-COUNTER HEARING AIDS
Sec. 710
REPORT ON SERVICING OF DEVICES
Sec. 801
PRIORITY REVIEW OF GENERIC DRUGS
Sec. 802
ENHANCING REGULATORY TRANSPARENCY TO ENHANCE GENERIC COMPETITION
Sec. 803
COMPETITIVE GENERIC THERAPIES
Sec. 804
ACCURATE INFORMATION ABOUT DRUGS WITH LIMITED COMPETITION
Sec. 805
SUITABILITY PETITIONS
Sec. 806
INSPECTIONS
Sec. 807
REPORTING ON PENDING GENERIC DRUG APPLICATIONS AND PRIORITY REVIEW APPLICATIONS
Sec. 808
INCENTIVIZING COMPETITIVE GENERIC DRUG DEVELOPMENT
Sec. 809
GAO STUDY OF ISSUES REGARDING FIRST CYCLE APPROVALS OF GENERIC MEDICINES
Sec. 901
TECHNICAL CORRECTIONS
Sec. 902
ANNUAL REPORT ON INSPECTIONS
Sec. 903
STREAMLINING AND IMPROVING CONSISTENCY IN PERFORMANCE REPORTING
Sec. 904
ANALYSIS OF USE OF FUNDS
Sec. 905
FACILITIES MANAGEMENT
Sec. 104.1
SUNSET DATES
Sec. 210.2
SUNSET DATES
Sec. 305.3
SUNSET DATES
Sec. 405.4
SUNSET DATES